Company profile: Ultivue
1.1 - Company Overview
Company description
- Provider of tissue imaging and multiplex biomarker assay solutions for precision medicine research, including InSituPlex DNA-barcoded antibody technology, custom assay development, pre-optimized ready-to-use multiplex staining kits, specialized AI tools and full lifecycle image analysis for multiplex immunofluorescence, and OmniVUE customizable biomarker panel design kits.
Products and services
- InSituPlex Technology: Research-grade multiplexing system employing DNA-barcoded antibodies to perform multiplex biomarker assays and deliver advanced tissue sample analysis for precision medicine research
- Pre-optimized Ready-to-Use Kits: Automation-compatible reagent assemblies that supply all components for multiplex staining on tissue slides, optimized for automated stainers or manual protocols
- Custom Assay Development: Custom-engineered program that architects tailored biomarker assays to meet specific research needs, including design, development, and execution
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ultivue
Clinical Laserthermia Systems
HQ: Sweden
Website
- Description: Provider of the TRANBERG® Thermal Therapy System and disposable materials for image-guided, minimally invasive laser ablation and heat-induced immunotherapy (imILT®), offering focal therapy for localized prostate cancer, careful therapy of brain lesions/epileptogenic foci, immune-stimulating laser ablation, and the Thermoguide Workstation for real-time treatment monitoring and control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clinical Laserthermia Systems company profile →
Gradalis
HQ: United States
Website
- Description: Provider of personalized cancer immunotherapy leveraging patients' own genetically modified tumor cells to enhance immune recognition and killing through its Vigil platform, and of clinical trials evaluating the safety and efficacy of Vigil across cancer types, including ovarian cancer and Ewing’s sarcoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gradalis company profile →
Novelos Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research, development, and commercialization focused on oxidized glutathione.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novelos Therapeutics company profile →
Clarient
HQ: United States
Website
- Description: Provider of cancer diagnostic testing and oncology diagnostic services in the United States, partnering with local pathologists and oncologists to bring the standard of care back to their communities, using multiple technologies to clarify complex problems, help diagnose cancer cases, and provide insight.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clarient company profile →
Exelixis
HQ: United States
Website
- Description: Provider of therapies for cancer and other serious diseases, discovering, developing and commercializing small-molecule and biotherapeutic treatments. Marketed products include CABOMETYX (cabozantinib) and COTELLIC (cobimetinib); MINNEBRO (esaxerenone) is marketed in Japan by Daiichi Sankyo. Offers clinical trials, early access to investigational medicines, and collaborations to advance experimental molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exelixis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ultivue
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ultivue
2.2 - Growth funds investing in similar companies to Ultivue
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ultivue
4.2 - Public trading comparable groups for Ultivue
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →